Theravance Biopharma (TBPH) Misses Q3 EPS by 7c

Theravance Biopharma (NASDAQ: TBPH) reported Q3 EPS of ($1.27), $0.07 worse than the analyst estimate of ($1.20). Revenue for the quarter came in at $4.3 million versus the consensus estimate of $4.61 million.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• Broadcom (AVGO) Tops Q2 EPS by 5c, Offers Guidance
• Are we witnessing a fundamental or speculative rally in the S&P 500?